| Evolent Pathways | Febrile Neutropenic Risk | Emetogenic Risk | References |
|---|---|---|
Bone Mets w/ solid tumors |
zoledronic acid *denosumab is pathway if patient has proven contraindication to zoledronic acid*
|
|
Multiple Myeloma |
zoledronic acid *denosumab is pathway if patient has proven contraindication to zoledronic acid* |
|
Non-Metastatic Adjuvant (to reduce breast cancer recurrence to the bone) |
zoledronic acid *postmenopausal defined as natural or induced by ovarian ablation/suppression; Hormone positive with adjuvant endocrine treatment; 4 mg IV q6 mos up to 5 years* *denosumab is pathway if patient has proven contraindication to zoledronic acid* |
|
Bone Mets w/ solid tumors
zoledronic acid *denosumab is pathway if patient has proven contraindication to zoledronic acid*
Multiple Myeloma
zoledronic acid *denosumab is pathway if patient has proven contraindication to zoledronic acid*
Non-Metastatic Adjuvant (to reduce breast cancer recurrence to the bone)
zoledronic acid *postmenopausal defined as natural or induced by ovarian ablation/suppression; Hormone positive with adjuvant endocrine treatment; 4 mg IV q6 mos up to 5 years* *denosumab is pathway if patient has proven contraindication to zoledronic acid*